Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P39877
UPID:
PA2G5_HUMAN
Alternative names:
PLA2-10; Phosphatidylcholine 2-acylhydrolase 5
Alternative UPACC:
P39877; Q8N435
Background:
Phospholipase A2 group V (PLA2G5), also known as PLA2-10 and Phosphatidylcholine 2-acylhydrolase 5, plays a pivotal role in lipid metabolism and immune response. It targets extracellular phospholipids, releasing fatty acids that influence macrophage polarization and contribute to lipid remodeling of cellular membranes. Its activities extend to promoting phagocytosis and exhibiting bactericidal action against Gram-positive bacteria, alongside roles in the biosynthesis of cysteinyl leukotrienes and regulation of IL33 production in pulmonary macrophages.
Therapeutic significance:
PLA2G5's involvement in Fleck retina, familial benign, underscores its potential in understanding retinal diseases. Its broad biological functions suggest that targeting PLA2G5 could offer novel therapeutic strategies for managing immune and inflammatory conditions.